INTRODUCTION
Thyroid cancer overdiagnosis results from the identification of small indolent cancers that, if left undiagnosed, would not lead to harm to the individual. 1 Despite the excellent prognosis of small thyroid cancers, many of those diagnosed receive extensive treatment including thyroidectomy, radioactive iodine and life-long thyroid hormone replacement. 2 The overdiagnosis and subsequent overtreatment are not only potentially harmful to individuals, they use considerable healthcare resources that might otherwise be directed to treating individuals with symptomatic disease. 3 In responding to the problem of thyroid cancer overdiagnosis, we argue that decisions about investigations and treatment should be addressed through public health interventions rather than left to the individual choices of patients and clinicians. First, we explain overdiagnosis and how thyroid cancer overdiagnosis occurs, before discussing the harms. Finally, we explain why an 'informed choice' approach to thyroid cancer overdiagnosis is unlikely to reduce harm; instead we argue for a public health approach for both ethical and pragmatic reasons.
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Addressing overdiagnosis is complicated by the fact that it is a difficult concept to explain and can generate much uncertainty among people encouraged to make informed choices about participating in screening programs. 14 And in a final twist, people who have or may have been overdiagnosed often regard themselves as 'cured' by the treatment rather than recognising or expressing concern that they might have been treated for a cancer that did not require intervention in the first place. 15
THYROID CANCER OVERDIAGNOSIS
Rates of thyroid cancer diagnosis have increased substantially around the world in recent decades. In South Korea, the rate rose 15-fold between 1993 and 2011, making it that country's commonest cancer. 16 The British age-standardised incidence more than doubled between 1975 and 2008 17 ; likewise rates doubled in the USA between the 1990s and the 2000s. 18 Similar rises have been observed in other countries. 19 The vast majority of the identified cancers are well-differentiated papillary thyroid cancers
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(PTC), including many < 1 cm in diameter, known as micro-papillary thyroid cancers (mPTC) . 20 There seem to be two principal sources of the extra diagnoses. In many countries, including Western Europe, the USA and South Korea, ultrasound examination of the thyroid is increasingly undertaken on a 'routine' basis, on people who are asymptomatic. 21 Thyroid cancers are also identified incidentally when ultrasound, computerised tomography (CT) and positron emission tomography (PET) are used during investigations for non-cancerous thyroid disease, cranial arterial disease, or other pathology in adjacent organs. 22 25 Lobectomy is a type of partial thyroidectomy in which a lobe of the thyroid is removed, conventionally taking the isthmus with it.
10 mean of thirteen years) found that patients who were deemed to be low risk and treated with only lobectomy suffered no reduction in cancer specific survival. 26 National guidelines are gradually moving towards risk-stratified approaches. British Thyroid Association guidelines recommend against 'routine' total thyroidectomy for tumours less than 4 cm in size; and for lobectomy only for unifocal mPTCs. 27 Likewise, the American Thyroid Association recommends lobectomy only for low risk tumours between 1-4 cm; and consideration of active surveillance for low risk mPTCs. 28 The ATA recommendation to consider active surveillance for mPTCs is based on Japanese research which suggests that any surgery may be unnecessary for patients with mPTC. 29 Over a fifteen year period, researchers found no significant difference in the rate of novel lymph node metastases in a group initially treated by observation only compared to lymph node recurrence in a group initially treated with surgery. Later surgery, triggered by tumour growth or clinical detection of lymph node disease, did not affect long-term recurrence or disease-specific survival. Thus there was no disadvantage to patients who were observed initially but whose cancer progressed compared with those receiving surgery at the time of diagnosis. Active surveillance did not lead to worse recurrence or survival outcomes than immediate surgery.
Given the natural history of thyroid cancer and the reliability of risk stratification, it might be suggested that thyroid cancer does not meet the overdiagnosis criterion of failure to track harmful disease. 30 But even though it is possible in principle to distinguish at diagnosis those patients with very small cancers for whom observation is a safe (and less harmful) course of action than immediate surgery, this information
has not yet been widely taken up in practice. 31 Thus thyroid cancer remains very much an overdiagnosed (and overtreated) condition. The published version of this paper is: Rogers WA, Craig WL and Entwistle VE. Ethical issues raised by thyroid cancer overdiagnosis: a matter for public health? Bioethics 2017; 31 (8): 590-598.
ETHICAL CONCERNS ASSOCIATED WITH THYROID CANCER
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A number of ethical issues arise regarding thyroid cancer overdiagnosis. We discuss these in three main clusters, focusing on negative implications for patients, negative implications for health services and societies, and conflicts of interest.
For individuals, harms may be both immediate and far-reaching. 32 Korea, the escalating rates of thyroid cancer are matched by escalating rates of thyroidectomy. 43 Where the costs of these extra services fall will depend to some extent upon the structure and funding of healthcare systems. Here we describe standard thyroid cancer Haugen et al., op. cit. note 28.) Due to lack of consistent routine follow up, it is not known whether outcomes differ between low-risk patients subject to regular surveillance versus those who re-present only when symptomatic (i.e. they or others notice a lump in their neck).
16 generate health gains. In the process, considerable resources are rendered unavailable for the treatment of other health problems, especially in fixed budget publicly funded systems. It is not feasible to pinpoint the opportunity costs of thyroid cancer overdiagnosis, but the rising rates of diagnosis and high costs of long-term follow up suggest this is likely a multi-billion dollar problem. 45 Ethical concern is exacerbated because resources are thereby diverted away from the prevention or treatment of symptomatic disease. 46 Not only do patients who miss out on their hip replacement or cataract operations have impaired quality of life, so too do those who have to live with the consequences of thyroid cancer overdiagnosis.
A third cluster of ethical concerns relate to the various conflicts of interest that arise in, and may contribute to, the overdiagnosis of thyroid cancer. Fee for service remuneration systems are likely to increase the routine use of high resolution ultrasounds and other imaging modalities, while rates of diagnosis and treatment may be exacerbated in systems in which primary care physicians, radiologists and surgeons are able to co-ordinate patient referrals to their mutual benefit (financial or otherwise). 47 In Korea, physicians often offer opportunistic thyroid cancer screening in conjunction with mandated screening for other conditions. 48
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There may be other structural conflicts of interest. For example, British surgical associations have previously required a minimum of twenty five cases of thyroid surgery per year (not necessarily all for cancer) for accreditation as a competent thyroid surgeon. 49 Targets based on patient volume may bias surgeons' risk assessments and communication with patients towards investigation and operation rather than surveillance.
CLINICAL ETHICS AND THYROID CANCER OVERDIAGNOSIS
Prima facie, thyroid cancer overdiagnosis might look like a matter for clinical ethics, to be dealt with using accepted frameworks for considering the appropriateness of interactions between individual practitioners and patients. 50 Within such frameworks, a focus on autonomous decision making tends to emphasise the provision of information and the need to ensure patients are: able to understand the potential benefits and harms (and perhaps the potentially conflicting interests of those offering intervention); and free to make an informed choice (perhaps supported by a process of shared decision-making). In this case attention would be directed to two key decision points: regarding an initial investigation that might lead to overdiagnosis; and regarding treatment of any identified lesions. The published version of this paper is: Rogers WA, Craig WL and Entwistle VE. Ethical issues raised by thyroid cancer overdiagnosis: a matter for public health? Bioethics 2017; 31 (8): 590-598.
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In the context of breast-cancer screening, investigators have been able to develop and deliver a decision aid that increases women's understanding of overdiagnosis as well as of the benefits of screening and risk of false positive results. 51 Theoretically, evidence about risk stratification might make decision-making about overdiagnosis easier to explain in the context of thyroid cancer. Nonetheless, the development and provision of decisions aids or other information resources about investigations with potential to trigger (over)diagnosis of thyroid cancer might be more complex than for breast cancer. In jurisdictions where thyroid scans have become a routine part of a 'check-up' (e.g. USA, Korea), it may be feasible and reasonable to propose the use of such resources in these contexts. However, there are multiple other pathways into the diagnosis of thyroid cancer that make information provision highly complex. For example, some investigations are clinically indicated (e.g. for neck pathology), so multiple and highly nuanced decision aids would be required. Some known barriers to the use of decision aids in practice 52 are also likely to be highly salient in this context, especially if clinicians strongly favour intervention. 51 While the results were significant, even with the decision aid only 29% of the women randomised to receive the decision aid had adequate overall knowledge of the Once a cancer is detected, patients are faced with further decisions. The little empirical evidence to date suggests that in at least some countries, shared decisionmaking is rare in the context of decisions about the management of thyroid cancer. A recent Australian study found patients were told that surgery would be 'curative' for their slow growing thyroid cancer; the option of surveillance was not raised, but some participants indicated that they would have been willing to accept surveillance rather than surgery. 53 This is consistent with the finding that some patients in the Japanese trial accepted surveillance instead of surgery. 54 In view of internationally rising rates of thyroid surgery, these findings tend to support the suspicion that doctors generally either do not offer a non-surgical option or present the choice in a way that encourages patients to opt for surgery.
Without empirical evidence, it is hard to predict the choices that more informed patients might make, but it seems unlikely that supporting informed-decision-making will stem current rates of overtreatment. Of course when ethical frameworks emphasise decisional autonomy, the options patients choose and the implications of these are sometimes taken to matter less than whether or not they reflect the patient's preferences. However, in the context of the various pressures and potential conflicts of interest noted above, we suggest it is particularly important to recognise the challenges of informing and ascertaining patients' preferences in ways that warrant the normative significance that this way of thinking places on them. 
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Given existing evidence about the reliability and safety of risk stratification, and the known harms of surgery, a widespread tendency to recommend or implicitly encourage surgery seems both clinically and ethically unwarranted.
Indeed doctors could be justified in advising against, or not offering, surgery to patients with low risk thyroid tumours, on the grounds that the harms will (almost certainly) outweigh any benefits they might receive, and that surgery wastes healthcare resources. There are, however, several interconnected barriers to such a significant change from current professional practice. 56 These include the emphasis on offering choice that is encouraged by strong focus within clinical ethics on decisional autonomy, a fear of medico-legal risk (e.g. if a patient offered surveillance suffered adverse outcomes from delayed treatment), and the various conflicts of interest mentioned above.
In summary, despite the merits of shared approaches to clinical decision-making, a clinical ethics approach that focuses on supporting more informed patient choice may do little to reduce the harms associated with thyroid cancer overdiagnosis. The main problems are that this approach does nothing to address the systemic drivers of thyroid cancer overdiagnosis and treatment, risks perpetuating some of the current inclinations towards intervention, and so will fail to stem the rising tide of individual and societal burdens and opportunity costs. A public health model is potentially more valuable for generating ethical responses to thyroid cancer overdiagnosis.
A PUBLIC HEALTH MATTER?
Box 1. Coggon's taxonomy of the seven faces of public health 61
In what follows, we draw on Coggon's understanding of public health to make the case for claiming that thyroid cancer overdiagnosis should be viewed as a public health matter; and to argue that potential strategies to decrease the harm from thyroid cancer overdiagnosis fall within activities usually taken to be those of public health. 
5.
Public health as blind benefit/harm: PH is a probabilistic approach to population health in which benefits/harms accrue to unidentified individuals. 6. Public health as conjoined beneficiaries: PH entails considering the health of people in a holistic manner such that any harm/benefit to an individual is also seen as a harm/benefit to their community. 7. Public health as the population's health: PH is a factual description of the aggregate health of populations.
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The significant increase in both the diagnosis (incidence) and treatment of thyroid cancer indicates that the aggregate health of the population (Coggon's sense seven) has deteriorated. As we have argued above, much of the increased incidence may be attributed to the detection of sub-clinical disease rather than a sudden rise in de novo thyroid cancers. Nonetheless, because of the rate and nature of interventions for overdiagnosed thyroid cancers, it seems reasonable to claim that the aggregate health of the population is worse than prior to the rise in detection because of the burden (often life-long) of treatments and associated morbidities from thyroid cancer overdiagnosis.
As well as harms to the health of individual patients (measurable at a population level), a number of the additional harms of thyroid cancer overdiagnosis that we discussed above (especially bankruptcy, decreased workforce participation, increased overall healthcare costs, diversion of resources and opportunity costs) affect communities as they affect individuals (Coggon's sense six of conjoined beneficiaries). In countries with public healthcare systems, the public purse is supporting considerable medical activity with little apparent benefit. In private healthcare systems, increased costs of treatment contribute to rapidly rising insurance premiums, which are a burden on the population who rely on insurance for their healthcare needs. Thinking of thyroid cancer as a community as well as an individual harm suggests solidarity-based (rather than solely self-regarding) reasons for avoiding overdiagnosis and overtreatment. This may encourage people to invoke other-
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regarding reasons for abstaining from thyroid cancer screening, analogous to herd immunity arguments that people consider regarding vaccination. 62 Coggon's sense three refers to public health in terms of social infrastructure: public health both reflects and is shaped by the social context. Thyroid cancer overdiagnosis might be considered a public health issue in this sense because in part it arises from and reflects the widely shared cultural phobias about cancer, exemplified by the axiom that, with cancer, it is 'better safe than sorry'. 63 This is evident in preferences to be tested, even for very slow growing cancers that would not cause problems, 64 and in a tendency to regard early detection as a way of minimising potential regret. 65 Poor understandings of risk generally -in both medical and lay populations -can exacerbate this prevailing attitude. The culture of litigation against medical practitioners, perhaps reinforced by inadequate social welfare arrangements for those disadvantaged by poor health, that is a feature of some jurisdictions, is another social
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• Regulating the use of diagnostic technologies known to contribute to overdiagnosis. Widespread uptake of high sensitivity neck imaging is a direct cause of thyroid cancer overdiagnosis, and use of this technology could be curtailed by, for example, limiting referral rights or access to rebates. 67
• Incentivising the use of polices about thyroid cancer treatment based upon risk stratification, 68 for example by withholding remuneration for practitioners who perform surgery against indications based upon stratification; or publishing audits of quality of care based on the guidelines mentioned above.
• Reviewing the organisation of surgical care, to minimise perverse incentives.
In the UK, management of thyroid disease has largely been transferred from general/thyroid surgeons to otorhinolaryngologists (ENT surgeons). Recent research suggests that ENT surgeons deliver more extensive surgery than general/thyroid surgeons for the same extent of disease or patient risk. 69 Thus the potential for overtreatment increases as the disease management becomes more specialised. As the organisation of surgical care falls within the remit of federal, national or local departments of health, these health agencies have the power and responsibility to prevent changes to care that increase harms. 67 We note professional concern about thyroid cancer overdiagnosis and the development of discussion papers and/or guidelines to address this (e.g. Haugen et al., The published version of this paper is: Rogers WA, Craig WL and Entwistle VE. Ethical issues raised by thyroid cancer overdiagnosis: a matter for public health? Bioethics 2017; 31 (8): 590-598.
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constrain medical practice in ways that are generally deemed acceptable. 73 Likewise, limiting exposure of individuals to investigations that precipitate overdiagnosis does not seem to be a worrying infringement of liberty, as this would not impede access to clinically indicated investigations. And offering patients in whom thyroid cancers are detected only those treatment options that are based on robust risk assessments seems consistent with good clinical care rather than an unwarranted restriction.
Under a public health-type approach, patients would be free to accept or reject proffered treatment (including surveillance), but they would not be free to request treatment that is not indicated by their level of risk, and therefore highly likely to be much more harmful than beneficial to them and their communities. We do not see this as undue rationing or undue paternalism, as the usual assumption in healthcare is that people are offered only effective treatments that are proportionate to the risk of their underlying condition. Most healthcare services are based on need and do not permit patients to choose treatments that are outside clinical indications. In addition, the reasons for limiting choice are not solely directed at the welfare of individual patients (although this is part of the motivation); as we have argued above, the public health is harmed by thyroid cancer overdiagnosis and this supports independent justifications for intervention.
CONCLUSION
In summary, there are several reasons to consider thyroid cancer overdiagnosis as a The published version of this paper is: Rogers WA, Craig WL and Entwistle VE. Ethical issues raised by thyroid cancer overdiagnosis: a matter for public health? Bioethics 2017; 31 (8): 590-598.
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intervention, rather than a matter solely to be considered at the level of individual clinical care. An approach based upon organisational policy and option-constraining regulation is likely to be more effective in shaping practice than voluntary professional regulation or a reliance on informed patient choice. In addition, since thyroid cancer overdiagnosis damages the public health, and many of the drivers are systemic, governments have a duty to take action rather than leaving decisions in the private realm.
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